Brian Leyland-Jones, MD, PhD
Georgia Cancer Coalition Distinguished Scholar and Professor and Director, Winship Cancer Institute, Emory University
Before joining Emory, Dr. Leyland-Jones was the Minda de Gunzberg Chair in Oncology and professor of medicine at McGill University in Montreal, Canada. From 1990 to 2000, he served as founding chair of Oncology and director of the McGill University Comprehensive Cancer Centre.
Dr. Leyland-Jones holds biochemistry, medical and doctoral degrees from the University of London. Following residency training at Hammersmith, Brompton, St. Bartholomew's and London hospitals, he completed a clinical pharmacology fellowship at Cornell University and a medical oncology fellowship at Memorial Sloan-Kettering Cancer Center. He then joined the academic staff at Memorial Sloan-Kettering Cancer Center and New York Hospitals with a special research interest in early clinical evaluation of new anti-cancer compounds.
In 1983, he moved to the National Cancer Institute (NCI) to head the Developmental Chemotherapy section. During his time with the NCI, he was responsible for the overall development of approximately 70 anti-cancer compounds in various stages of transition from in-vitro screening to Phase III clinical trials.
During his tenure as director of the McGill Comprehensive Cancer Centre, Dr. Leyland-Jones led development of a clinical trials operation that integrated research with five clinical trial cooperative groups and more than 40 pharmaceutical companies. Cancer-related clinical trials at McGill currently include more than 100 protocols at any one time and are structured through nine multidisciplinary disease sections throughout the Cancer Centre. Dr. Leyland-Jones also initiated new sections of epidemiology and cancer pharmacology, increasing the Cancer Centre's research space and adding several new associate and full professorial appointments. In addition, he worked closely with the Montreal community to establish eight endowed chairs and several fellowships within the department.
Dr. Leyland-Jones' main research interests are pharmacodynamics, pharmacokinetics and pharmacogenetics in oncological clinical trials; translation of preclinical models into the clinic; biomarker endpoints in Phase I/II clinical trials; and screening and mechanistic studies of novel targeted and chemotherapeutic anti-cancer agents. He has authored more than 125 peer-reviewed articles and book contributions, 150 abstracts and 29 patents.
Dr. Leyland-Jones holds leadership positions on numerous committees, including the Breast Cancer International Working Group/National Cancer Institute Cooperative Group; the Board of Directors for the National Cancer Institute of Canada; the Breast International Group, and the Herceptin Adjuvant Committee. He also serves on editorial boards for Cancer Chemotherapy and Pharmacology; British Journal of Cancer; Clinical Proteomics; and The International Journal of IN VIVO Research, among others.